MedTrace Logo

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

NCT04042558 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-05-12

Study results available
· View outcomes & findings →

Summary

The objective of this study is to assess the efficacy of the combination of Platinum (carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage IIIB/IV non-squamous non-small cell lung cancer patients with progression-enhancing mutations following targeted therapies.

Conditions

  • NSCLC Stage IIIB
  • NSCLC Stage IV
  • EGFR Gene Mutation
  • ALK Gene Rearrangement Positive
  • ROS1 Gene Mutation

Interventions

DRUG

Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab

4 cycles of induction every 3 weeks of cisplatine,pemetrexed, atezolizumab + bevacizumab and patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed +/- Bevacizumab administered at the same dosage on 3-week cycles

DRUG

Carboplatin + Pemetrexed + Atezolizumab

Carboplatin + Pemetrexed + Atezolizumab

Sponsors & Collaborators

  • GFPC

    collaborator UNKNOWN

  • Centre Francois Baclesse

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-26
Primary Completion
2021-10-22
Completion
2025-04-09

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04042558 on ClinicalTrials.gov